Top in dermatology: Therapies for basal cell carcinoma, molluscum contagiosum show promise

Early data from a phase 1/2 trial showed promising results for AIV001, AiViva Biopharma’s intradermal basal cell carcinoma treatment, according to a company press release.
“We are excited to have completed this safety study that is demonstrating excellent skin tolerability and a dose response,” Diane Tang-Liu, PhD, president and CEO of AiViva, said in the release.
It was the top story in dermatology last week.
Another top story reported positive results from a phase 3 trial in Japan that investigated a treatment for molluscum contagiosum. Torii Pharmaceutical, a partner of

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.